Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2026
Primary Event: Announcement of positive interim Phase 2 clinical data for INBRX-106 in first-line Head and Neck Squamous Cell Carcinoma (HNSCC).
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on clinical developments and does not contain audited financial statements, revenue, profit, cash flow, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Clinical Results
The Company reported interim results from the randomized Phase 2 portion of the HexAgon study evaluating INBRX-106 (a hexavalent OX40 agonist) plus pembrolizumab versus pembrolizumab monotherapy in treatment-naïve, PD-L1 positive (CPS ≥ 20) HNSCC.
- Study Population: 68 patients enrolled (33 combination, 35 control). Interim analysis based on 53 evaluable patients (25 combination, 28 control).
- Confirmed Objective Response Rate (ORR): 44.0% (11/25) in the INBRX-106 combination arm versus 21.4% (6/28) in the control arm, representing a 22.6% absolute increase.
- Complete Responses: 3 observed in the combination arm; 0 in the control arm.
- Pharmacodynamics: Combination arm showed up to 15-fold increase in T-cell proliferation and 4-fold increase in activation compared to control.
- Safety: Generally manageable; most common adverse events were rash, diarrhea, fatigue, and infusion-related reactions (predominantly low-grade). No treatment-related deaths reported.
Guidance, Outlook, and Risks
Development Timeline:
- Phase 3 HexAgon Study: Planned to begin in Q3 2026.
- Progression-Free Survival (PFS) Data: Expected in Q4 2026.
- NSCLC Expansion: Perioperative study initiation expected later in Q2 2026; front-line metastatic NSCLC studies expected to begin in 2027.
Market Opportunity: The Company estimates a total potential market size of approximately $50 billion if INBRX-106 expands across all checkpoint inhibitor indications ($1B for HNSCC, $25B for NSCLC, and $25B for other indications).
Risks and Contingencies:
- Interim data may not be representative of final results or data from the remaining 15 patients.
- Early clinical trial results are not necessarily predictive of future results.
- Risks regarding regulatory approvals, commercialization, pricing, and reimbursement.
- Potential for unexpected adverse side effects or inadequate efficacy.
Investor Verification Checklist
- Verify the final Phase 2 data readout in Q4 2026, specifically regarding the remaining 15 patients not included in the interim analysis.
- Monitor the initiation timeline for the Phase 3 HexAgon study scheduled for Q3 2026.
- Review the safety profile in the full dataset to confirm the absence of severe adverse events as the trial matures.
- Assess the Company's cash runway and capital requirements given the planned expansion into NSCLC and Phase 3 trials.
- Confirm the regulatory strategy and potential for accelerated approval pathways based on the 22.6% absolute increase in response rate.